Released Nov 14, 2024, before the open
10-Q filed Nov 14, 2024, 45 days after period end · 0001558370-24-015612
Q3 2024 · 10-Q
Revenue$17.96M$17.96M +73.6% vs Q3 2023+33.3% vs Q2 2024
Net Income$3.24M$3.24M N/M vs Q3 2023N/M vs Q2 2024
EPS Diluted$0.03$0.03 N/M vs Q3 2023N/M vs Q2 2024
Operating Income$3,991,000N/M
Operating Cash Flowderived$4,105,000N/M
Free Cash Flowderived$4,018,000N/M
Margins · derived
Operating margin22.2%+40.5 pt vs Q3 2023
Net margin18.0%+35.9 pt vs Q3 2023
What the release said
The release
Same quarter
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $17.96M | $10.35M | $14.18M | $12.05M |
| Net Income | $3.24M | -$1.85M | -$3.57M | -$4.20M |
| EPS Diluted | $0.03 | -$0.04 | -$0.07 | -$0.09 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR